ArticleACS measurement science au2022
Ultralow Limit Detection of Soluble HER2 Biomarker in Serum with a Fiber-Optic Ball-Tip Resonator Assisted by a Tilted FBG.
Article in ACS measurement science au, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 42 citations in OpenAlex.
- Sensitive detection of surface-mounted micrometer-thin cancer biomarkers and viruses using laser wave-mixing spectroscopy.Biomedical optics express · 2026Article
- Review
- Overview of Optical Fiber Biosensors for the Detection of Cancer Biomarkers in the Past Decade.ACS omega · 2026Review
- Evanescent wave-based optical biosensors for innovations, medical application and future perspectives.Journal of advanced research · 2026Review
- Electrochemical aptasensing of HER2 breast cancer biomarker using a Ni nanofoam/Ag-Au ternary nanocomposite.Analytical and bioanalytical chemistry · 2026Article
- Functionalization Techniques Empowering Optical Fiber Biosensors in Label-Free Cancer Biomarker Detection.Biosensors · 2025Review
- HER2-Low Breast Cancer at the Interface of Pathology and Technology: Toward Precision Management.Biomedicines · 2025Review
- Shining the Path of Precision Diagnostic: Advancements in Photonic Sensors for Liquid Biopsy.Biosensors · 2025Review
- Advancements in Battery Monitoring: Harnessing Fiber Grating Sensors for Enhanced Performance and Reliability.Sensors (Basel, Switzerland) · 2024Review
- Dynamic Measurement of a Cancer Biomarker: Towards In Situ Application of a Fiber-Optic Ball Resonator Biosensor in CD44 Protein Detection.Sensors (Basel, Switzerland) · 2024Article
- All-fiber label-free optical fiber biosensors: from modern technologies to current applications [Invited].Biomedical optics express · 2024Review
- Unpacking the packaged optical fiber bio-sensors: understanding the obstacle for biomedical application.Frontiers in bioengineering and biotechnology · 2024Review
- A Novel NanoMIP-SPR Sensor for the Point-of-Care Diagnosis of Breast Cancer.Micromachines · 2023Article
- Spatial-Division Multiplexing Approach for Simultaneous Detection of Fiber-Optic Ball Resonator Sensors: Applications for Refractometers and Biosensors.Biosensors · 2022Article
- Carbon Nanopowder-Based Stochastic Sensor for Ultrasensitive Assay of CA 15-3, CEA and HER2 in Whole Blood.Nanomaterials (Basel, Switzerland) · 2022Article
- Label-free optical biosensors in the pandemic era.Nanophotonics (Berlin, Germany) · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
An optical-fiber biosensor has been developed for the detection of the breast cancer biomarker soluble human epidermal growth factor receptor-2 (sHER2). The sensor was fabricated by combining a tilted fiber Bragg grating (TFBG) with a ball resonator, allowing us to achieve an excellent sensitivity compared to other optical-fiber-based sensors. The sensor exhibits a resonance comb excited by the TFBG and the spectral profile of the ball resonator. The detection of sHER2 at extremely low concentrations was carried out by tracking the amplitude change of selected resonances. The therapeutic anti-HER2 monoclonal antibody Trastuzumab has been used to functionalize the biosensor with silane surface chemistry. The sensor features a sensitivity of 4034 dB/RIU with a limit of detection (LoD) in buffer and in a 1/10 diluted serum of 151.5 ag/mL and 3.7 pg/mL, respectively. At relatively high protein concentrations (64 ng/mL) binding to sHER (7.36 dB) as compared to control proteins (below 0.7 dB) attested the high specificity of sHER2 detection.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.